[Form 4] Fulgent Genetics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Fulgent Genetics (FLGT) insider transaction: the company’s Chief Scientific Officer reported a small sale of common stock tied to tax obligations. On 11/24/2025, the officer sold 535 shares of Fulgent Genetics common stock at a weighted-average price of $30.473 per share. The sale was coded as a disposition of securities in an open-market transaction.

According to the disclosure, these shares were sold solely to cover tax withholding that arose when previously granted restricted stock units vested. After this transaction, the officer reported beneficial ownership of 954,908 shares of Fulgent Genetics common stock, held directly.

Insider Trade Summary

Net Seller: 535 shares ($16,303)

Net Sell 1 txn

Insider Gao Hanlin

Role Chief Scientific Officer

Sold 535 shs ($16K)

Type	Security	Shares	Price	Value
Sale	Common Stock	535	$30.473	$16K

Holdings After Transaction: Common Stock — 954,908 shares (Direct)

Footnotes (1)

1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. The shares were sold in multiple transactions at prices ranging from $30.33 to $30.62, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gao Hanlin

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CA 91731

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/24/2025		S		535(1)	D	$30.473(2)	954,908	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023.

2. The shares were sold in multiple transactions at prices ranging from $30.33 to $30.62, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

	/s/ Paul Kim as Attorney-in-Fact	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Fulgent Genetics (FLGT) report?

Fulgent Genetics reported that its Chief Scientific Officer sold 535 shares of common stock on 11/24/2025 in a transaction disclosed on Form 4.

At what price were the Fulgent Genetics (FLGT) shares sold in this Form 4?

The 535 shares were sold at a weighted-average price of $30.473 per share, based on multiple trades between $30.33 and $30.62.

Why did the Fulgent Genetics officer sell shares in this filing?

The filing states the shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 23, 2023.

How many Fulgent Genetics (FLGT) shares does the insider own after the sale?

Following the reported transaction, the Chief Scientific Officer beneficially owned 954,908 shares of Fulgent Genetics common stock, held directly.

What role does the reporting person hold at Fulgent Genetics (FLGT)?

The reporting person serves as Chief Scientific Officer of Fulgent Genetics, as indicated in the Form 4.

Was this Fulgent Genetics (FLGT) insider sale executed in multiple trades?

Yes. The filing explains the shares were sold in multiple transactions at prices ranging from $30.33 to $30.62, with the reported price being a weighted average.